BUZZ-Revvity’s third-quarter results surpass expectations, stock poised for best single-day performance in 16 years

Latest Updates

November 3 - ** Medical device manufacturer Revvity’s share price RVTY.N rose by 11%, reaching $168.10

** The share price hit its highest level since April 2022, and is on track for the largest single-day gain since August 2010

** The company raised its adjusted full-year earnings per share (EPS) outlook from $5.30–$5.40 to $5.40–$5.45

** Full-year total revenue is expected to be about $2.86 billion, compared with previous expectations of $2.83 to $2.86 billion

** Report shows third-quarter (link) revenue was $729 million, beating analysts’ projections of $698.15 million — data compiled by LSEG

** Life sciences segment revenue rose 11% year-on-year, and diagnostics segment revenue was up 4% over the same period last year

** Third-quarter adjusted EPS was $1.37, also above the $1.30 estimate

** Out of 19 analysts, 6 have a “Buy” or higher rating on the stock, with the rest at “Hold”; median price target is $155

**Including today’s gain, the stock is up 36.55% year-to-date, while the S&P 500 Healthcare Index is up over 19% .SPXHC in the same period

(To aid non-English speakers, Reuters automatically translates its reports into several other languages. As automated translation may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of the translated text, which is provided for reader convenience only. Reuters accepts no liability for any damage or loss resulting from the use of automated translation.)